Investors
Stock Quote
ICCC Stock Price
Data provided by Yahoo Finance. Prices may be delayed. Not financial advice.
Press Releases
Recent News | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014
SEC Filings
SEC Filings
Annual Report and Proxy
Corporate
Governance
ICCC Code of Conduct
Charter and Powers of the Audit Committee
Nominating Committee Charter
Management & Directors
ImmuCell Corporation (Nasdaq: ICCC) is an animal-health biologics company that operates in the fast-growing market for calf health solutions. It develops, manufactures and commercializes the First Defense® line of products to protect newborn calves against scours (neonatal calf diarrhea), a leading cause of death that the Company estimates costs U.S. industry up to $1 billion per year. First Defense® is USDA-licensed franchise of scours prevention products and a stable revenue and profit growth driver.
Recent News
- 04-08-26 – ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
- 03-18-26 ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
- 03-04-26 ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
Recent Quarterly Filing
2026 Meeting of Stockholders
Thursday, June 11, 2026, beginning at 9:30 AM ET
2025 Meeting of Stockholders
Thursday, June 12, 2025 at 9:30 AM ET
Proxy Statement
Webcast
Conference Calls
Company Contact
Olivier te Boekhorst
President & CEO
investor.relations@immucell.com
Investor Contact
Lytham Partners, LLC
iccc@lythampartners.com
602.889.9700